300 related articles for article (PubMed ID: 25972070)
1. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.
Srivastava RM; Trivedi S; Concha-Benavente F; Hyun-Bae J; Wang L; Seethala RR; Branstetter BF; Ferrone S; Ferris RL
Cancer Immunol Res; 2015 Aug; 3(8):936-45. PubMed ID: 25972070
[TBL] [Abstract][Full Text] [Related]
2. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
4. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.
Leibowitz MS; Srivastava RM; Andrade Filho PA; Egloff AM; Wang L; Seethala RR; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Feb; 19(4):798-808. PubMed ID: 23363816
[TBL] [Abstract][Full Text] [Related]
5. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
6. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
Faden DL; Concha-Benavente F; Chakka AB; McMichael EL; Chandran U; Ferris RL
Head Neck; 2019 Aug; 41(8):2591-2601. PubMed ID: 30828910
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.
Leibowitz MS; Andrade Filho PA; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2011 Apr; 60(4):525-35. PubMed ID: 21207025
[TBL] [Abstract][Full Text] [Related]
8. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
Pai SI; Jack Lee J; Carey TE; Westra WH; Ferrone S; Moore C; Mosunjac MB; Shin DM; Ferris RL;
Oral Oncol; 2018 Feb; 77():92-97. PubMed ID: 29362132
[TBL] [Abstract][Full Text] [Related]
9. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Shayan G; Kansy BA; Gibson SP; Srivastava RM; Bryan JK; Bauman JE; Ohr J; Kim S; Duvvuri U; Clump DA; Heron DE; Johnson JT; Hershberg RM; Ferris RL
Clin Cancer Res; 2018 Jan; 24(1):62-72. PubMed ID: 29061643
[No Abstract] [Full Text] [Related]
10. Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.
Concha-Benavente F; Srivastava RM; Trivedi S; Lei Y; Chandran U; Seethala RR; Freeman GJ; Ferris RL
Cancer Res; 2016 Mar; 76(5):1031-43. PubMed ID: 26676749
[TBL] [Abstract][Full Text] [Related]
11. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.
Concha-Benavente F; Srivastava R; Ferrone S; Ferris RL
Oral Oncol; 2016 Jul; 58():52-8. PubMed ID: 27264839
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
13. IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells.
Carbotti G; Nikpoor AR; Vacca P; Gangemi R; Giordano C; Campelli F; Ferrini S; Fabbi M
J Exp Clin Cancer Res; 2017 Oct; 36(1):140. PubMed ID: 29020964
[TBL] [Abstract][Full Text] [Related]
14. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract][Full Text] [Related]
15. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Marijt KA; Sluijter M; Blijleven L; Tolmeijer SH; Scheeren FA; van der Burg SH; van Hall T
J Immunother Cancer; 2019 Jun; 7(1):152. PubMed ID: 31196219
[TBL] [Abstract][Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
Moon C; Chae YK; Lee J
Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
19. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Jie HB; Schuler PJ; Lee SC; Srivastava RM; Argiris A; Ferrone S; Whiteside TL; Ferris RL
Cancer Res; 2015 Jun; 75(11):2200-10. PubMed ID: 25832655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]